View Older Stories View More Recent Stories

Jan 7, 2021 08:30AM CORRECTING and REPLACING Syros to Present at 39th Annual J.P. Morgan Healthcare Conference
Dec 8, 2020 04:39PM Syros Closes $90.5 Million Strategic Financing
Dec 7, 2020 05:56AM Syros Pharmaceuticals (SYRS) Acquires Clinical-Stage Drug Candidate, SY-2101, for Acute Promyelocytic Leukemia from Orsenix, LLC
Dec 5, 2020 12:31PM Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML
Dec 5, 2020 12:31PM Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies
Nov 16, 2020 08:00AM Syros Pharmaceuticals to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
Nov 5, 2020 04:01PM Syros Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Nov 4, 2020 10:12AM Syros to Present New Data from Phase 2 Clinical Trial of SY-1425 in Oral Presentations at 62nd ASH Annual Meeting
Oct 29, 2020 08:30AM Syros to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
Oct 26, 2020 06:36AM Syros Pharmaceuticals (SYRS) Highlights Initial Data from Phase 1 Clinical Trial of SY-5609
Oct 24, 2020 07:30AM Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting
Oct 9, 2020 07:30AM Syros to Present Initial Data from Phase 1 Clinical Trial of SY-5609 at EORTC-NCI-AACR Meeting
Sep 10, 2020 08:30AM Syros Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference
Sep 9, 2020 08:35AM Syros Pharmaceuticals (SYRS) Announces S. Gail Eckhardt, M.D. to Board
Sep 9, 2020 08:31AM Syros Announces Appointment of S. Gail Eckhardt, M.D., to its Board of Directors
Aug 6, 2020 07:31AM Syros Reports Second Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Aug 5, 2020 09:09AM Syros Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Jul 30, 2020 08:30AM Syros to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Jun 17, 2020 08:00AM Syros Announces Change to Presentation Time at JMP Securities Hematology and Oncology Forum
Jun 11, 2020 08:31AM Syros to Present Virtually at JMP Securities Hematology and Oncology Forum
May 29, 2020 08:01AM Syros Presents New Preclinical Data on SY-5609 at 2020 ASCO Virtual Scientific Program
May 13, 2020 05:01PM Syros to Present New Preclinical Data on SY-5609 at ASCO Virtual Scientific Program
May 7, 2020 07:30AM Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
Apr 30, 2020 08:30AM Syros to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020
Mar 5, 2020 07:30AM Syros Reports Fourth Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Feb 27, 2020 08:00AM Syros to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 5, 2020
Feb 24, 2020 08:00AM Syros to Present at Upcoming Investor Conferences in March
Feb 13, 2020 08:00AM Syros Announces $60 Million Loan Facility with Oxford Finance LLC
Jan 29, 2020 08:36AM Syros Pharmaceuticals (SYRS) Presents New Preclinical Data Highlighting Its Leadership in CDK Inhibition
Jan 29, 2020 08:31AM Syros Presents New Preclinical Data Highlighting Its Leadership in CDK Inhibition to Discover and Develop New Medicines for Difficult-to-Treat Cancers
Jan 28, 2020 08:41AM Syros Pharmaceuticals (SYRS) Reports First Patient Dosed in Phase 1 Clinical Trial of SY-5609
Jan 28, 2020 08:31AM Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-5609, Its Highly Selective and Potent Oral CDK7 Inhibitor, in Patients with Select Solid Tumors
Jan 12, 2020 09:00AM Syros Announces Strategic Priorities and Expected Milestones
Dec 20, 2019 08:05AM Syros Pharmaceuticals (SYRS) Names Mark Alles to Board
Dec 20, 2019 08:01AM Syros Announces Appointment of Mark Alles to Its Board of Directors
Dec 18, 2019 08:57AM Global Blood Therapeutics (GBT) Secures $150 Million Non-Dilutive Term Loan Financing
Dec 18, 2019 07:15AM GBT Secures $150 Million Non-Dilutive Term Loan Financing
Dec 18, 2019 07:02AM Global Blood Therapeutics (GBT) and Syros Partner (SYRS) to Discover, Develop and Commercialize Novel Therapies for SCD and Beta Thalassemia
Dec 18, 2019 07:00AM GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia
Dec 8, 2019 08:00AM Syros Presents on Identification of Novel Fetal Hemoglobin Repressor as Part of Broader Drug Discovery Program in Sickle Cell Disease at 61st Annual ASH Meeting
Nov 26, 2019 08:31AM Syros to Present at Piper Jaffray 31st Annual Healthcare Conference
Nov 19, 2019 07:01AM Syros to Present on Core Drivers of Metastasis in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium
Nov 12, 2019 08:00AM Syros Reports Third Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Nov 6, 2019 09:01AM Syros to Present on Sickle Cell Disease Research at 61st Annual ASH Meeting
Nov 5, 2019 08:30AM Syros to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
Oct 29, 2019 05:13PM Syros Pharmaceuticals (SYRS) New Preclinical Data on SY-5609
Oct 29, 2019 04:01PM Syros Presents New Preclinical Data on SY-5609, Its Highly Selective Oral CDK7 Inhibitor, at AACR-NCI-EORTC International Conference
Oct 24, 2019 08:34AM Syros Pharmaceuticals (SYRS) Reports New Data from Ph. 2 Trial of SY-1425 in Combination with Azacitidine
Oct 24, 2019 08:31AM Syros Announces New Data from Phase 2 Trial of SY-1425 in Combination with Azacitidine Demonstrating High Response Rates, Rapid Onset of Action and Favorable Tolerability Profile in RARA-Positive Newl
Oct 17, 2019 07:02AM Syros Pharmaceuticals (SYRS) Announces Update on Selective CDK7 Inhibitor Portfolio
View More Recent Stories View Older Stories